Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07212179 · ClinicalTrials.gov registry record · NA

Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery

A NA study of Type 1 Diabetes, sponsored by Anas El Fathi.

Recruiting
Registry status
NA
Development phase
6
Enrollment target
1
Study location

NCT07212179 is a NA study of Type 1 Diabetes that is actively recruiting participants, run by Anas El Fathi. The registered enrollment target is 6 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07212179, a NA study of Type 1 Diabetes, is actively recruiting participants, sponsored by Anas El Fathi.

RECRUITING
Registry status
NA
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

To evaluate the safety and feasibility of a novel self-learning bolus calculator along with simplified meal announcement (AID+InsuLearn-SMA) in adolescents and young adults with T1D using Automated Insulin Delivery.

Conditions Studied

Interventions

  • DEVICE AID + InsuLearn-SMA
  • DEVICE AID + CC

Study Locations (1)

Virginia

  • University of Virginia Center for Diabetes Technology - Charlottesville

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2026-03-03
Est. Completion 2026-12-31
Phase NA

Sponsor

Anas El Fathi

1 total trials

What the Registry Record Tells You About NCT07212179

The ClinicalTrials.gov registry entry for NCT07212179 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is Anas El Fathi, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which AID + InsuLearn-SMA is the first listed.

NCT07212179 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT07212179 about?

NCT07212179 is a clinical study titled "Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery". To evaluate the safety and feasibility of a novel self-learning bolus calculator along with simplified meal announcement (AID+InsuLearn-SMA) in adolescents and young adults with T1D using Automated Insulin Delivery.

What is the current status of trial NCT07212179?

This trial is currently recruiting. It is a NA study. The enrollment target is 6 participants. The study started on 2026-03-03. Estimated completion is 2026-12-31.

What conditions does trial NCT07212179 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT07212179?

The interventions under investigation include: AID + InsuLearn-SMA (DEVICE), AID + CC (DEVICE).

Who is sponsoring clinical trial NCT07212179?

This trial is sponsored by Anas El Fathi, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07212179 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.